The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
about
Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapiesRole of HOXA9 in leukemia: dysregulation, cofactors and essential targetsRomidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative dataENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapyCafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.Ligand Based Pharmacophore Modeling and Virtual Screening Studies to Design Novel HDAC2 Inhibitors.An evidence-based review of obatoclax mesylate in the treatment of hematological malignanciesTrichostatin-A modulates claudin-1 mRNA stability through the modulation of Hu antigen R and tristetraprolin in colon cancer cells.Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms.Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeletonRisk-adapted strategies for the treatment of Hodgkin lymphoma.An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
P2860
Q26744080-DBA5C378-08F9-41DB-9602-AD6DB93B1844Q28082027-58044E81-F6E0-4466-B39A-903EC528F8B6Q30936712-5F8DD988-A4C3-4AE7-AF22-CAC1D008355DQ33432027-C63559CF-12A5-4308-9E67-BB42122262A1Q33983255-ED58471A-1279-4729-AC3F-78E7661F6B78Q34004454-8DE9323B-4FB6-404A-9658-D411D2F80671Q34662207-49C1CCAF-BCF6-4545-93B5-5B6B3A3F962CQ34695894-1D2DC4C4-1951-41E8-8F16-F8042289F6BBQ36696524-057F8158-6E47-44DE-948D-26140713E590Q37262149-3D5BBD0B-A466-4CC3-96E7-AA30376CA29AQ37983083-3D67AD15-9917-4D63-B6D1-48F750F3B35AQ38193997-359C01BD-CF15-4293-97EE-63E14A934817Q38478630-D2FDA5E0-4E9F-41C8-8117-4CF9B5FE332AQ38591137-8B2F49D1-C1E6-4A70-9A9D-4CFCE2DF7917Q38765451-E190FA6B-64F0-456C-BD04-706E39B0B49AQ38906418-E7E41B3D-681D-4405-945D-25816F9C7A84
P2860
The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The histone deacetylase inhibi ...... with Bcl-2 family inhibitors.
@ast
The histone deacetylase inhibi ...... with Bcl-2 family inhibitors.
@en
type
label
The histone deacetylase inhibi ...... with Bcl-2 family inhibitors.
@ast
The histone deacetylase inhibi ...... with Bcl-2 family inhibitors.
@en
prefLabel
The histone deacetylase inhibi ...... with Bcl-2 family inhibitors.
@ast
The histone deacetylase inhibi ...... with Bcl-2 family inhibitors.
@en
P2093
P2860
P1476
The histone deacetylase inhibi ...... s with Bcl-2 family inhibitors
@en
P2093
Anas Younes
Arpád Illés
Catherine M Bollard
Daniela Buglio
Jessica A Shafer
L Jeffrey Medeiros
Noor Khaskhely
P2860
P304
1007-1017.e1
P356
10.1016/J.EXPHEM.2011.07.002
P577
2011-07-20T00:00:00Z